These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30130706)

  • 1. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
    Oleaga C; Riu A; Rothemund S; Lavado A; McAleer CW; Long CJ; Persaud K; Narasimhan NS; Tran M; Roles J; Carmona-Moran CA; Sasserath T; Elbrecht DH; Kumanchik L; Bridges LR; Martin C; Schnepper MT; Ekman G; Jackson M; Wang YI; Note R; Langer J; Teissier S; Hickman JJ
    Biomaterials; 2018 Nov; 182():176-190. PubMed ID: 30130706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS).
    Sakolish C; Reese CE; Luo YS; Valdiviezo A; Schurdak ME; Gough A; Taylor DL; Chiu WA; Vernetti LA; Rusyn I
    Toxicology; 2021 Jan; 448():152651. PubMed ID: 33307106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
    Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.
    Dionísio F; Araújo AM; Duarte-Araújo M; Bastos ML; Guedes de Pinho P; Carvalho F; Costa VM
    Arch Toxicol; 2022 Feb; 96(2):653-671. PubMed ID: 35088106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs.
    Oleaga C; Bernabini C; Smith AS; Srinivasan B; Jackson M; McLamb W; Platt V; Bridges R; Cai Y; Santhanam N; Berry B; Najjar S; Akanda N; Guo X; Martin C; Ekman G; Esch MB; Langer J; Ouedraogo G; Cotovio J; Breton L; Shuler ML; Hickman JJ
    Sci Rep; 2016 Feb; 6():20030. PubMed ID: 26837601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human iPSC-based cardiac microphysiological system for drug screening applications.
    Mathur A; Loskill P; Shao K; Huebsch N; Hong S; Marcus SG; Marks N; Mandegar M; Conklin BR; Lee LP; Healy KE
    Sci Rep; 2015 Mar; 5():8883. PubMed ID: 25748532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
    Nair P; Prado M; Perea-Gil I; Karakikes I
    Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
    Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
    Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
    Csöbönyeiová M; Polák Š; Danišovič L
    Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):887-902. PubMed ID: 33612039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
    Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
    Elife; 2021 Aug; 10():. PubMed ID: 34338636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.